Humana (NYSE:HUM) had its target price raised by stock analysts at MED from $350.00 to $373.00 in a research note issued to investors on Thursday, The Fly reports. The brokerage presently has an “outperform” rating on the insurance provider’s stock. MED’s price objective indicates a potential upside of 10.05% from the company’s current price.
Several other research firms have also commented on HUM. Cowen assumed coverage on shares of Humana in a report on Monday, September 17th. They issued a “market perform” rating and a $372.00 price target on the stock. SunTrust Banks upped their price target on shares of Humana to $380.00 and gave the company a “hold” rating in a report on Wednesday, September 19th. Credit Suisse Group upped their price target on shares of Humana from $350.00 to $370.00 and gave the company an “outperform” rating in a report on Tuesday, September 4th. Argus upped their price target on shares of Humana to $375.00 and gave the company a “buy” rating in a report on Tuesday, September 4th. Finally, Zacks Investment Research lowered shares of Humana from a “buy” rating to a “hold” rating in a report on Friday, October 5th. Seven investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Humana presently has a consensus rating of “Buy” and a consensus target price of $352.30.
Shares of HUM traded down $0.64 during trading hours on Thursday, reaching $338.95. 780,088 shares of the company traded hands, compared to its average volume of 655,197. The firm has a market capitalization of $48.77 billion, a PE ratio of 25.36, a price-to-earnings-growth ratio of 1.73 and a beta of 1.03. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.43. Humana has a 12-month low of $231.90 and a 12-month high of $355.88.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share for the quarter, beating analysts’ consensus estimates of $4.29 by $0.29. The firm had revenue of $14.21 billion for the quarter, compared to analyst estimates of $13.97 billion. Humana had a net margin of 2.70% and a return on equity of 19.36%. During the same period in the previous year, the company earned $3.39 earnings per share. As a group, research analysts anticipate that Humana will post 14.44 EPS for the current fiscal year.
In related news, insider Elizabeth D. Bierbower sold 3,092 shares of the company’s stock in a transaction dated Thursday, August 16th. The shares were sold at an average price of $330.00, for a total transaction of $1,020,360.00. Following the completion of the transaction, the insider now owns 14,289 shares in the company, valued at approximately $4,715,370. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Bruce D. Broussard sold 18,000 shares of the company’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the transaction, the chief executive officer now owns 71,085 shares of the company’s stock, valued at approximately $23,362,796.10. The disclosure for this sale can be found here. Corporate insiders own 0.60% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC raised its position in shares of Humana by 1.4% during the 3rd quarter. FMR LLC now owns 12,379,797 shares of the insurance provider’s stock worth $4,190,809,000 after purchasing an additional 167,283 shares during the last quarter. BlackRock Inc. raised its position in shares of Humana by 1.2% during the 3rd quarter. BlackRock Inc. now owns 12,311,736 shares of the insurance provider’s stock worth $4,167,767,000 after purchasing an additional 140,731 shares during the last quarter. Northern Trust Corp raised its position in shares of Humana by 1.2% during the 2nd quarter. Northern Trust Corp now owns 1,687,211 shares of the insurance provider’s stock worth $502,164,000 after purchasing an additional 20,480 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Humana by 7.6% during the 2nd quarter. Acadian Asset Management LLC now owns 1,324,681 shares of the insurance provider’s stock worth $394,262,000 after purchasing an additional 93,021 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Humana by 4.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 804,090 shares of the insurance provider’s stock worth $272,199,000 after purchasing an additional 35,845 shares during the last quarter. Hedge funds and other institutional investors own 92.62% of the company’s stock.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Featured Story: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.